Your session is about to expire
← Back to Search
T Cell Immunotherapy for Non-Hodgkin's Lymphoma
Study Summary
This trial is testing a new T cell immunotherapy for patients with indolent non-Hodgkin's lymphoma who have relapsed or are refractory to other treatments. The primary endpoint is efficacy, and secondary endpoints are safety and changes in various blood cell counts and immune responses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is a specific type of lymphoma or leukemia.I have had 1-4 treatments for non-Hodgkin lymphoma.My condition was diagnosed as stage III or IV at some point.My condition worsened or didn't improve after my last treatment.I have recently been treated with specific therapies.I have not had any cancer other than non-Hodgkin lymphoma in the past 5 years.My lymphoma is of an aggressive subtype.I am on medication for an autoimmune disease.I have a slow-growing type of non-Hodgkin's Lymphoma.I have recently been treated for an infection.I can take care of myself and am up and about more than half of my waking hours.My liver and kidneys are working well.My major organs are functioning properly.I have been diagnosed with T cell lymphoma.I have received steroids or IVIG recently.I am 18 years old or older.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What precautions have been taken to ensure the safety of those receiving this therapy?
"This experimental treatment has not yet been proven to be efficacious in clinical trials, thus receiving a safety score of 2."
What criteria should a potential participant meet to qualify for this research trial?
"This trial is recruiting 40 participants with non-Hodgkin's Lymphoma, who must meet the following criteria: be of age 18 or above; have had at least one prior course of systemic therapy but not more than four courses (single agent rituximab excluded); belong to any subtype according to the REAL Classification except mantle cell lymphoma and small lymphocytic lymphoma which are limited respectively to 8 and 16 patients; have Stage III or IV disease at some point in their medical history; present as either refractory or relapsed after most recent treatment, depending on time to disease progression; possess an EC"
In which geographical areas can participants access this trial?
"18 sites are participating in this medical trial. These locations include the Cancer Institute of New jersey in New Brunswick, Oregon Health Sciences University in Portland, and Rocky Mountain Cancer Centers located in Denver to name a few."
Is this experiment actively seeking participants?
"According to the clinicaltrials.gov database, this trial is not actively recruiting participants. The first posting was on March 1st 2004 and it has been since edited the last time being June 23rd 2005. Though inactive at present, there are an abundance of alternate trials currently searching for patients - 1778 in total!"
Is there an age cutoff for inclusion in this analysis?
"This medical investigation is seeking participants that are 18 years old or older and younger than 80."
Share this study with friends
Copy Link
Messenger